Romergoline (FCE 23884) is an ergoline derivative and a dopamine receptor agonist and antagonist. Its action depends on the functional state of the biological substrate, mostly related to the presence or absence of dopamine. In healthy animals, it behaves as a full dopamine antagonist, but in denervated models it behaves as an agonist. Therefore, romergoline was suggested to be potentially useful in both psychotic states and extrapyramidal diseases. In Parkinson patients, the degree of dopamine receptor stimulation was found to be insufficient to improve symptoms. Information about further development of romergoline is not available.